Deutsche Bank’s ProQR Therapeutics PRQR Stock Holding History

Deutsche Bank’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$176K	Hold	108,762	–	–	﹤0.01%	3055
2025 Q4	$220K	Hold	108,762	–	–	﹤0.01%	2973
2025 Q3	$232K	Hold	108,762	–	–	﹤0.01%	2984
2025 Q2	$222K	Hold	108,762	–	–	﹤0.01%	2903
2025 Q1	$145K	Hold	108,762	–	–	﹤0.01%	3089
2024 Q4	$288K	Hold	108,762	–	–	﹤0.01%	2938
2024 Q3	$198K	Sell	108,762 -276,387	-72%	-$519K	﹤0.01%	2933
2024 Q2	$639K	Hold	385,149	–	–	﹤0.01%	2217
2024 Q1	$882K	Sell	385,149 -59	-0%	-$126	﹤0.01%	2071
2023 Q4	$763K	Buy	+385,208	New	+$592K	﹤0.01%	2168
2023 Q3	–	Sell	-385,208	Closed	-$624K	–	3798
2023 Q2	$624K	Hold	385,208	–	–	﹤0.01%	2238
2023 Q1	$820K	Hold	385,208	–	–	﹤0.01%	2217
2022 Q4	$1.43M	Hold	385,208	–	–	﹤0.01%	1848
2022 Q3	$287K	Hold	385,208	–	–	﹤0.01%	2721
2022 Q2	$300K	Hold	385,208	–	–	﹤0.01%	2914
2022 Q1	$349K	Sell	385,208 -121,410	-24%	-$407K	﹤0.01%	2953
2021 Q4	$4.06M	Sell	506,618 -74,184	-13%	-$565K	﹤0.01%	1560
2021 Q3	$4.86M	Sell	580,802 -697	-0.1%	-$4.55K	﹤0.01%	1526
2021 Q2	$3.92M	Sell	581,499 -123,381	-18%	-$796K	﹤0.01%	1695
2021 Q1	$4.66M	Buy	704,880 +523,953	+290%	+$2.68M	﹤0.01%	1584
2020 Q4	$760K	Buy	+180,927	New	+$763K	﹤0.01%	2636
2020 Q1	–	Sell	-3,645	Closed	-$36K	–	4714
2019 Q4	$36K	Sell	3,645 -34,338	-90%	-$267K	﹤0.01%	4092
2019 Q3	$217K	Buy	37,983 +20,268	+114%	+$162K	﹤0.01%	3142
2019 Q2	$159K	Sell	17,715 -3,546	-17%	-$41.8K	﹤0.01%	3957
2019 Q1	$293K	Buy	21,261 +12,488	+142%	+$187K	﹤0.01%	3776
2018 Q4	$137K	Buy	+8,773	New	+$161K	﹤0.01%	4068
2017 Q4	–	Sell	-9,500	Closed	-$46K	–	5101
2017 Q3	$46K	Buy	+9,500	New	+$49.3K	﹤0.01%	4394
2016 Q4	–	Sell	-1,447	Closed	-$9K	–	5039
2016 Q3	$9K	Sell	1,447 -13,460	-90%	-$74.1K	﹤0.01%	4687
2016 Q2	$71K	Buy	14,907 +12,907	+645%	+$66.4K	﹤0.01%	4254
2016 Q1	$9K	Sell	2,000 -13,336	-87%	-$67.8K	﹤0.01%	4852
2015 Q4	$132K	Buy	15,336 +13,436	+707%	+$155K	﹤0.01%	3921
2015 Q3	$27K	Sell	1,900 -23,241	-92%	-$389K	﹤0.01%	4681
2015 Q2	$418K	Buy	25,141 +2,083	+9%	+$39.2K	﹤0.01%	3499
2015 Q1	$504K	Buy	23,058 +11,740	+104%	+$242K	﹤0.01%	3289
2014 Q4	$245K	Sell	11,318 -12,830	-53%	-$195K	﹤0.01%	4191
2014 Q3	$415K	Buy	+24,148	New	+$387K	﹤0.01%	3625

Other funds holding PRQR

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Deutsche Bank's PRQR Position: Q1 2026 in Review

Deutsche Bank held its ProQR Therapeutics (PRQR) position steady in Q1 2026 at 108,762 shares worth $176K. The position accounts for ﹤0.01% of the portfolio, ranked #3055.

Deutsche Bank first reported a position in PRQR in Q3 2014 and has held it in 36 quarters since. The position peaked at $4.86M in Q3 2021. 69 funds tracked by Wall St. Rank hold PRQR as of Q1 2026.

Deutsche Bank held 108,762 shares of ProQR Therapeutics worth $176K as of Q1 2026.
Deutsche Bank left its ProQR Therapeutics share count unchanged in Q1 2026.
ProQR Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #3055 holding.
Deutsche Bank first reported a position in ProQR Therapeutics in Q3 2014 and has held it in 36 quarters since.
Deutsche Bank's ProQR Therapeutics position peaked at $4.86M in Q3 2021.
69 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.